Emerging pharmacologic therapies for constipation-predominant irritable bowel syndrome and chronic constipation

Shanti Eswaran, Amanda Guentner, William D. Chey*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Irritable bowel syndrome with constipation and chronic functional constipation are common digestive disorders that negatively impact quality of life and account for billions of dollars in health care costs. Related to the heterogeneity of pathogenesis that underlie these disorders and the failure of symptoms to reliably predict underlying pathophysiology, traditional therapies provide relief to only a subset of affected individuals. The evidence surrounding new and emerging pharmacologic treatments, which include both luminally and systemically acting drugs, is discussed here. These include agents such as lubiprostone, bile acid modulations, guanylate cyclase-C receptor agonists, serotonin receptor modulators and herbal therapies.

Original languageEnglish (US)
Pages (from-to)141-151
Number of pages11
JournalJournal of Neurogastroenterology and Motility
Volume20
Issue number2
DOIs
StatePublished - 2014

Keywords

  • Bile acid and salts
  • Constipation
  • Irritable bowel syndrome
  • Laxatives
  • Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Emerging pharmacologic therapies for constipation-predominant irritable bowel syndrome and chronic constipation'. Together they form a unique fingerprint.

Cite this